Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/3/2024 | $50.00 | Overweight | Wells Fargo |
| 5/22/2023 | $35.00 → $38.00 | Buy | Jefferies |
| 9/19/2022 | $27.00 | Outperform | Wedbush |
| 8/26/2022 | $31.00 | Overweight | Piper Sandler |
| 11/12/2021 | $18.00 → $23.00 | Buy | Canaccord Genuity |
| 9/13/2021 | $25.00 | Buy | HC Wainwright & Co. |
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
Canaccord Genuity analyst Edward Nash maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $35 to $37.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Verona Pharma (NASDAQ:VRNA) with a Buy and maintains $36 price target.
Truist Securities analyst Joon Lee maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $32 to $38.
10-Q - Verona Pharma plc (0001657312) (Filer)
8-K - Verona Pharma plc (0001657312) (Filer)
144 - Verona Pharma plc (0001657312) (Subject)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
4 - Verona Pharma plc (0001657312) (Issuer)
Wells Fargo initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $50.00
Jefferies resumed coverage of Verona Pharma with a rating of Buy and set a new price target of $38.00 from $35.00 previously
Wedbush resumed coverage of Verona Pharma with a rating of Outperform and set a new price target of $27.00
SC 13G/A - Verona Pharma plc (0001657312) (Subject)
SC 13G/A - Verona Pharma plc (0001657312) (Subject)
SC 13G - Verona Pharma plc (0001657312) (Subject)
LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, FL A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company's website, www.veronapharma.com. For further information please contact: Verona Pharma plcTel: +1-844-341-9901Victoria Stewart, Senior Director of Investor Relations and [email protected] Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartne
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the third quarter ended September 30, 2024, and provides a corporate update. "We are pleased to report an exceptionally strong st
LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States+1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Compan